We provide stem cell-derived human respiratory cells to users who wish to utilize them in drug discovery assays and toxicity safety studies. We also offer customized differentiation of iPS cells into respiratory epithelial cells on a per-contract basis.

We have succeeded in efficiently generating human respiratory cells -which had long been known to be difficult to culture- from human stem cells. We will apply this technology and integrate it into a product/servicing package suitable for drug discovery assays and toxicity safety testing, for clients such as pharmaceutical companies, chemical companies, research institutes. Currently, we offer contract production of respiratory epithelial cells and optimization of differentiation induction methods to meet the needs of users.

If you are interested, please contact us.

We have been conducting drug discovery research using our proprietary in vitro disease models, initially for rare diseases such as cystic fibrosis and idiopathic pulmonary fibrosis, with plans to expand further into other more common diseases including oncology.

We are utilizing our respiratory cell regeneration technology for replication of both normal human lung/respiratory tract physiology and for disease pathophysiology in lungs, utilizing patient iPS cells particularly in the latter use case. Both of these can be utilized as drug discovery platforms, and we have sought out academic and industry partners, while also conducting in-house pharmaceutical research and development to further validate our platform more directly. We are already involved in several projects related to rare diseases such as cystic fibrosis and idiopathic pulmonary fibrosis, and emerging infectious diseases including COVID-19. We have plans to further expand into other disease areas, and we welcome potential partners willing to collaborate with us and exploit our drug discovery platform.

If you are interested, please contact us.

We are conducting research to realize cell- and tissue-based therapies that enable lung regeneration at the organ and structure level for diseases and conditions that have not been well-addressed by conventional molecular pharmacological treatment concepts.